Cover Image
市場調查報告書

歐洲的新型胰島素市場分析

European Market Report for Modern Insulin 2016 - MedCore

出版商 iData Research Inc. 商品編碼 370781
出版日期 內容資訊 英文 89 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
歐洲的新型胰島素市場分析 European Market Report for Modern Insulin 2016 - MedCore
出版日期: 2016年09月01日 內容資訊: 英文 89 Pages
簡介

歐洲的胰島素市場,分類對速效型、持久性功效型、預混合胰島素的3種,而其中持久性功效型胰島素佔整體市場的約50%。專利到期和新產品的上市,產品單價 (ASP)的提高等,成為持久性功效型胰島素市場主要推動因素。

本報告提供歐洲各國的新型胰島素 (速效型、持久性功效型胰島素類似物等)的市場相關分析,疾病概要和主要的治療方法,整體市場規模的成果值、預測值,各產品詳細趨勢,主要的推動及阻礙市場要素等的調查評估。

摘要整理

歐洲的糖尿病監測、治療、藥物遞送市場

競爭分析

市場趨勢

市場發展

分析對象市場

主要報告的更新情形

過去的版本

調查手法

  • 調查範圍
  • IDATA的9個等級分析方法

疾病概要

  • 簡介
    • 糖尿病的種類
    • 糖尿病的併發症
    • 第一型、第二型糖尿病的相關風險要素
    • 前兆、症狀
    • 糖尿病監測
    • 治療方法
    • 藥物遞送系統 (藥物輸送設備)

各國市場簡介

  • 簡介
    • 人口
    • 每人GDP
    • 價格指數
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 荷比盧三國
  • 北歐各國
  • 奧地利
  • 瑞士
  • 葡萄牙

MODERN INSULIN MARKET

  • 簡介
    • 胰島素的種類
      • 速效型胰島素類似物
      • 通常型胰島素注射液
      • 中間型胰島素
      • 持久性功效型胰島素類似物
      • 超持久性功效型胰島素類似物
  • 市場概要
  • 市場分析與預測
    • 新型胰島素整體市場
    • 持久性功效型胰島素市場
    • 速效型胰島素市場
    • 預混合胰島素市場
  • 推動及阻礙市場要素
    • 推動市場要素
    • 阻礙市場要素
  • 各企業市場佔有率分析

簡稱一覽

目錄
Product Code: iDATA_EUDD16_MC_IM

The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern insulin market was the long-acting insulin segment, which represented nearly 50% of the total market value. Patent expirations and the introduction of new products will lead to higher unit sales growth in this segment, relative to the rapid-acting insulin and premixed insulin segments. Combined with modest appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total modern insulin market over the forecast period.

Insulin is a hormone that causes glucose uptake from the blood through the cells of the liver, muscle and fat tissue to be stored as glycogen in the liver and muscle. Type 1 diabetics' immune systems destroy pancreatic beta cells: the only cells that can make insulin. The body therefore fails to produce insulin and cannot naturally convert food into energy. Type 2 diabetics have a resistance to insulin, and cells are not able to use the insulin present in the body. The need for insulin increases to the point that the pancreas can no longer produce it. Insulin is therefore a mode of treating both type 1 and type 2 diabetes.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

EUROPEAN MARKET FOR DIABETES MONITORING, TREATMENT AND DRUG DELIVERY

COMPETITIVE ANALYSIS

MARKET TRENDS

MARKET DEVELOPMENTS

MARKETS INCLUDED

KEY REPORT UPDATES

VERSION HISTORY

RESEARCH METHODOLOGY

  • 1.1 RESEARCH SCOPE
  • 1.2 IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 2.1. INTRODUCTION
    • 2.1.1. Types of Diabetes
    • 2.1.2. Diabetes Complications
    • 2.1.3. Risk Factors Associated with Type 1 and Type 2 Diabetes
    • 2.1.4. Signs and Symptoms
    • 2.1.5. Diabetes Monitoring
    • 2.1.6. Treatment
    • 2.1.7. Drug Delivery Systems

COUNTRY PROFILES

  • 3.1. INTRODUCTION
    • 3.1.1.1. Population
    • 3.1.1.2. GDP Per Capita
    • 3.1.1.3. Units
  • 3.2. GERMANY
  • 3.3. FRANCE
  • 3.4. UNITED KINGDOM
  • 3.5. ITALY
  • 3.6. SPAIN
  • 3.7. BENELUX
  • 3.8. SCANDINAVIA
  • 3.9. AUSTRIA
  • 3.10. SWITZERLAND
  • 3.11. PORTUGAL

MODERN INSULIN MARKET

  • 4.1. INTRODUCTION
    • 4.1.1. Insulin Types
      • 4.1.1.1. Rapid-Acting Insulin Analogs
      • 4.1.1.2. Regular Human Insulin
      • 4.1.1.3. Intermediate-Acting Insulin Analogs
      • 4.1.1.4. Long-Acting Insulin Analogs
      • 4.1.1.5. Ultra-Long-Acting Insulin Analogs
  • 4.2. MARKET OVERVIEW
  • 4.3. MARKET ANALYSIS AND FORECAST
    • 4.3.1. Total Modern Insulin Market
    • 4.3.2. Long-Acting Insulin Market
    • 4.3.3. Rapid-Acting Insulin Market
    • 4.3.4. Premixed Insulin Market
  • 4.4. DRIVERS AND LIMITERS
    • 4.4.1. Market Drivers
    • 4.4.2. Market Limiters
  • 4.5. COMPETITIVE MARKET SHARE ANALYSIS

ABBREVIATIONS

Back to Top